Share Email Print

Proceedings Paper

Photodynamic therapy with Photofrin II by bronchial artery infusion
Author(s): Tetsuya Okunaka; Harubumi Kato; Chimori Konaka; Komei Kinoshita; Kimito Yamada
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Photodynamic therapy (PDT) utilizing Photofrin II is proving to be an effective modality in the treatment of early stage lung cancer. However, wider clinical application of Photofrin II as a photosensitizer for various cancers is hampered by the potentially serious and prolonged skin photosensitivity. To prevent these side effects and reduce the inpatient period, we recently tried to give reduced doses of Photofrin II by bronchial artery infusion (BAI). Six patients with endoscopically evaluated early stage carcinoma of the lung were given 0.7 mg/kg of Photofrin II by BAI 48 hours before PDT. Complete remission was obtained in all 6 cases, and there was no evidence of skin photosensitivity when exposed to outside light under careful surveillance at one week after PDT.

Paper Details

Date Published: 5 March 1993
PDF: 4 pages
Proc. SPIE 1616, International Conference on Photodynamic Therapy and Laser Medicine, (5 March 1993); doi: 10.1117/12.136982
Show Author Affiliations
Tetsuya Okunaka, Tokyo Medical College (Japan)
Harubumi Kato, Tokyo Medical College (Japan)
Chimori Konaka, Tokyo Medical College (Japan)
Komei Kinoshita, Tokyo Medical College (Japan)
Kimito Yamada, Tokyo Medical College (Japan)

Published in SPIE Proceedings Vol. 1616:
International Conference on Photodynamic Therapy and Laser Medicine
Junheng Li, Editor(s)

© SPIE. Terms of Use
Back to Top